Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio4t2 Starts China Trial of BT-001 Antigen CAR-T for Solid Tumor Cancers

publication date: Jan 12, 2023

Bio4t2, a San Diego-Shanghai CAR-T company, dosed the first patient in a China trial of its CAR-T that targets the BT-001 antigen. Overexpression of BT-001 antigen occurs in several types of solid tumors. The CAR-T (B4t2-001) was developed from Bio4t2's PrismCore™ platform, which combines algorithmic learning with and iterative CAR designs, generating genetically modified T cells with specific effector functions. The Phase 1 investigator-initiated study will assess the safety, tolerability, pharmacodynamic and preliminary efficacy of the autologous CAR-T as a single agent after lymphodepletion. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital